Arvinas (NASDAQ:ARVN) Price Target Lowered to $48.00 at Barclays

Arvinas (NASDAQ:ARVN) had its price target reduced by Barclays from $60.00 to $48.00 in a report published on Wednesday, Benzinga reports. Barclays currently has an overweight rating on the stock.

ARVN has been the topic of a number of other research reports. Wedbush reiterated an outperform rating and set a $57.00 price target on shares of Arvinas in a research report on Tuesday, July 30th. Stifel Nicolaus dropped their price target on shares of Arvinas from $72.00 to $68.00 and set a buy rating on the stock in a research note on Wednesday, May 8th. Wells Fargo & Company reduced their price objective on shares of Arvinas from $63.00 to $60.00 and set an overweight rating for the company in a research report on Thursday, May 9th. HC Wainwright reiterated a buy rating and issued a $87.00 target price on shares of Arvinas in a research report on Friday, May 17th. Finally, Oppenheimer reduced their price target on shares of Arvinas from $70.00 to $50.00 and set an outperform rating for the company in a research report on Wednesday. Two investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Arvinas has an average rating of Moderate Buy and a consensus price target of $58.33.

Arvinas Price Performance

NASDAQ:ARVN opened at $25.84 on Wednesday. The company has a 50 day moving average price of $27.74 and a 200-day moving average price of $35.82. Arvinas has a 1-year low of $13.57 and a 1-year high of $53.08. The firm has a market cap of $1.77 billion, a price-to-earnings ratio of -4.36 and a beta of 1.98.

Arvinas (NASDAQ:ARVN) last released its quarterly earnings data on Tuesday, July 30th. The company reported ($0.49) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.08) by $0.59. The firm had revenue of $76.50 million during the quarter, compared to analysts’ expectations of $33.27 million. The firm’s quarterly revenue was up 40.4% on a year-over-year basis. During the same period in the previous year, the firm posted ($1.25) EPS. On average, sell-side analysts anticipate that Arvinas will post -3.67 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of ARVN. American International Group Inc. raised its stake in Arvinas by 1.8% during the first quarter. American International Group Inc. now owns 24,857 shares of the company’s stock worth $1,026,000 after purchasing an additional 449 shares during the period. Principal Financial Group Inc. lifted its holdings in Arvinas by 3.8% in the first quarter. Principal Financial Group Inc. now owns 13,307 shares of the company’s stock valued at $549,000 after acquiring an additional 486 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its holdings in Arvinas by 9.2% in the first quarter. Allspring Global Investments Holdings LLC now owns 12,570 shares of the company’s stock valued at $519,000 after acquiring an additional 1,060 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S purchased a new position in Arvinas in the first quarter worth approximately $44,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Arvinas by 21.7% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,033 shares of the company’s stock worth $372,000 after acquiring an additional 1,611 shares during the last quarter. Institutional investors and hedge funds own 95.19% of the company’s stock.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.